Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
The participants were divided into the following experimental groups or a placebo group: 1 mg of retatrutide (subcutaneously) 4 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 4 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 12 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg Here are the detailed results of the trial at 24 weeks and 48 weeks: Phase II clinical trial projects promising results of retatrutide in weight management
Importantly, AOD-9604 does not bind to growth hormone receptors or stimulate IGF-1 production, which distinguishes it from full-length human growth hormone
B., Zoricic, I., Sever, M.,
These peptides serve a prescriber population in anti-aging medicine, endocrinology, and metabolic health that had limited alternatives during the restriction period
US$ 29.96
US$ 29.04
US$ 23.02
US$ 24.18
US$ 25.09
US$ 29.07
US$ 26.39
